Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of “Buy” from Analysts

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has earned a consensus recommendation of “Buy” from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $62.50.

A number of research analysts have weighed in on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a research report on Monday, January 6th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Jasper Therapeutics in a report on Tuesday, March 11th. UBS Group initiated coverage on Jasper Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $38.00 price target for the company. Finally, Royal Bank of Canada reduced their price objective on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research note on Thursday, January 9th.

Jasper Therapeutics Trading Up 2.5 %

Shares of JSPR opened at $3.71 on Friday. The stock’s fifty day simple moving average is $5.23 and its 200 day simple moving average is $13.39. Jasper Therapeutics has a twelve month low of $3.13 and a twelve month high of $29.36. The firm has a market capitalization of $55.73 million, a P/E ratio of -0.78 and a beta of 2.55.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.35). Sell-side analysts predict that Jasper Therapeutics will post -4.47 earnings per share for the current year.

Institutional Trading of Jasper Therapeutics

Several large investors have recently modified their holdings of the business. Jane Street Group LLC purchased a new position in Jasper Therapeutics in the third quarter valued at about $251,000. Barclays PLC raised its position in shares of Jasper Therapeutics by 320.7% in the 3rd quarter. Barclays PLC now owns 16,146 shares of the company’s stock valued at $304,000 after purchasing an additional 12,308 shares in the last quarter. Wellington Management Group LLP purchased a new position in shares of Jasper Therapeutics during the 3rd quarter valued at approximately $447,000. FMR LLC acquired a new stake in shares of Jasper Therapeutics during the third quarter worth approximately $722,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Jasper Therapeutics by 239.8% in the third quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company’s stock worth $308,000 after buying an additional 11,567 shares during the last quarter. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.